Results 11 to 20 of about 21,795 (202)

Therapeutic Efficacy and Safety Profile of Eplontersen in Hereditary Transthyretin-Mediated Amyloidosis: A Systematic Review. [PDF]

Health Sci Rep
ABSTRACT Background Hereditary transthyretin‐mediated amyloidosis (hATTR) is a disorder that affects several body systems and can result in life‐threatening conditions like cardiomyopathy and polyneuropathy. For treatment of hATTR in the new medical realm, there is a breakthrough discovery of a medicine called Eplontersen, which targets the underlying ...
Patel ZV, Kumari V, Paras, Deepak BL, Prajjwal P, Deep KN, Bai R, John SS, Hussin OA.   +8 more
europepmc   +2 more sources

Transthyretin amyloidosis [PDF]

Nursing, 2020
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment.
Renáta Aiglová, Miloš Táborský, Pavla Flodrová, Alexander Schee   +3 more
openaire   +3 more sources

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources

Negative [99mTc]Tc -DPD Scintigraphy, Presence of Monoclonal Protein and Biopsy Suggestive of AL Amyloidosis in a Patient With Homozygous p.Ala101Val Transthyretin Gene Variant. [PDF]

Clin Case Rep
ABSTRACT Amyloidosis is a rare disease associated with the deposition of misfolded proteins that damage multiple organs, leading to a wide range of symptoms. The most frequently implicated proteins in amyloidosis include immunoglobulin Free Light Chains (FLC), related to AL amyloidosis, and transthyretin (TTR), which is responsible for ATTR amyloidosis.
Kryszpin P, Jachimowski P, Augustowski Ł, Ziarkiewicz M, Basak G, Lipowska M, Legatowicz-Koprowska M, Ziarkiewicz-Wróblewska B, Gawor-Prokopczyk M.   +8 more
europepmc   +2 more sources

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca, Beyer, Ruxandra, Manole, Simona, Chirilă, Alina, Dădârlat-Pop, Alexandra, Minciună, Ioan Alexandru, Pop, Dana   +6 more
openaire   +2 more sources

EGCG-Mediated Protection of Transthyretin Amyloidosis by Stabilizing Transthyretin Tetramers and Disrupting Transthyretin Aggregates

International Journal of Molecular Sciences, 2023
Transthyretin amyloidosis (ATTR) is a progressive and systemic disease caused by the misfolding and amyloid aggregation of transthyretin (TTR). Stabilizing the TTR tetramers and disrupting the formed TTR aggregation are treated as a promising strategy for the treatment of ATTR.
Huizhen Zou, Shuangyan Zhou
openaire   +2 more sources

Spectrum of transthyretin gene mutations and clinical characteristics of Polish patients with cardiac transthyretin amyloidosis

Cardiology Journal, 2022
BACKGROUND: Transthyretin amyloidosis (ATTR) is a rare, life-threatening systemic disorder. We present first findings on the cardiac hereditary ATTR in Poland.
Monika Gawor, Katarzyna Holcman, Maria Franaszczyk, Marta Lipowska, Piotr Michałek, Anna Teresińska, Zofia T. Bilińska, Paweł Rubiś, Magdalena Kostkiewicz, Wojciech Szot, Piotr Podolec, Jacek Grzybowski   +11 more
doaj   +1 more source

Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report

Journal of Medical Case Reports, 2018
Background Transthyretin amyloidosis is a systemic disorder caused by extracellular deposition of insoluble amyloid fibrils in peripheral and autonomic nerves, heart, kidney, gastrointestinal tract, and other organs.
Hiroyuki Yamamoto, Toru Hashimoto, Shunji Kawamura, Michiaki Hiroe, Taro Yamashita, Yukio Ando, Tomoki Yokochi   +6 more
doaj   +1 more source

Hereditary transthyretin amyloidosis overview [PDF]

Neurological Sciences, 2020
AbstractHereditary amyloidogenic transthyretin (ATTRv) amyloidosis is a rare autosomal dominantly inherited disorder caused by mutations in the transthyretin (TTR) gene. The pathogenetic model of ATTRv amyloidosis indicates that amyloidogenic, usually missense, mutations destabilize the native TTR favouring the dissociation of the tetramer into ...
Manganelli, Fiore, Fabrizi, Gian Maria, Luigetti, Marco, Mandich, Paola, Mazzeo, Anna, Pareyson, Davide   +5 more
openaire   +5 more sources